HBV Mutation Detail Information

> L80I Search Result

Mutation Information

Mutation Site	L80I
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Combined Mutation	rt.M204I+rt.L80I
Relevant Drug	lamivudine (LAM)
Country	Iran

Literature Information

PubMed PMID	23596461
Disease	Hepatocellular carcinoma; Chronic hepatitis B; Liver cirrhosis; Acute hepatitis B; Fulminant hepatitis B
Published Year	2013
Journal	Hepatitis monthly
Title	Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients.
Author	Mahabadi M,Norouzi M,Alavian SM,Samimirad K,Azad TM,Saberfar E,Mahmoodi M,Ramezani F,Karimzadeh H,Malekzadeh R,Montazeri G,Nejatizadeh A,Ziaee M,Abedi F,Ataei B,Yaran M,Sayad B,Hossein Somi M,Sarizadeh G,Sanei-Moghaddam I,Mansour-Ghanaei F,Rafatpanah H,Pourhosseingholi MA,Keyvani H,Kalantari E,Saberifiroozi M,Ali Judaki M,Ghamari S,Daram M,Fazeli Z,Goodarzi Z,Khedive A,Moradi A,Jazayeri SM
Evidence	Cross-resistance mutations to lamivudineand telbivudinewere: M204I 2.76% (9/325), M204V 1.23% (4/325), M204V/I + L180M 2.45% (8/325), and L80I + M204I 1.23% (4/325). Cross-resistance mutations to lamivudine and entecavirwere: M204I 2.76% (9/325) and M204V/I + L180M 2.45% (8/325) (Figure 1).

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation